Some of Wednesday's midday movers:» Read More
When Jim Cramer tells a caller that he needs to do homework he's not kidding. Here's his research.
*Facebook buys Oculus for $2 billion. NEW YORK, March 26- U.S. stocks rose on Wednesday as geopolitical tensions over Ukraine appeared to ease and the latest U.S. economic data pointed to improving conditions. Russia and the West drew a tentative line under the Ukraine crisis after U.S.
There’s a vicious new trend underway in the market and Cramer says stocks of perfectly good companies could take a big hit.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
What technology niche is attracting a ton of IPO buzz for companies that don’t generate a cent of revenue? Think it's social media? Think biotech.
There is worry that the recent decline in copper and China's economic woes might be the start of a wider correction.
March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
With economic data muted and the stock market in rally mode, Jim Cramer thinks these stocks are likely to attract bulls.
Companies of all sizes are staying in sync by launching career apps to find social media-savvy candidates who fit the company's culture.
If there's a Holy Grail in the stock market, Cramer says it's got to be this.
Some of the names on the move ahead of the open.
*L'Oreal does not need to sell Sanofi stake for Nestle deal. *Hopes recede for debt-funded buyback of stake by Sanofi.
Feb 11- Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7- $1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3 percent before the opening bell. It is marketed by Bayer AG in Europe.
“These are the kind of stocks you can fall back on, in moments where the market gets clobbered,” said Cramer.
Some of Wednesday's midday movers:
Cramer said this stock may be his best pick in the entire history of the Mad Money TV show.
Not all CEOs are created equal. Who should you believe in? Jim Cramer has faith in the following 5 top executives.
The jobs report may have changed the landscape, entirely. That makes next week's earnings all the more critical.